Jasper AI Conference Highlights Excitement for ChatGPT, Generative AI

  • Jasper, an AI startup, hosted what it promises was the 1st convention committed to generative AI.
  • Using position in San Francisco, the party hosted a packed group of 1,200 attendees. 
  • The temper was reminiscent of crypto buzz, but attendees mentioned generative AI is here to remain.

“It can be a action forward in humanity,” just one VC reported of generative AI. An executive when compared it to the Gutenberg printing push. 1 CEO known as the technologies “not just hoopla, but one thing real.” 

That is how 3 attendees — Sameer Dholakia, a spouse at Bessemer Enterprise Associates Greg Larson, the vice president of engineering at Jasper and Dario Amodei, the CEO of Anthropic, respectively — described the sizzling new subset of artificial intelligence at a conference named Gen AI in San Francisco on February 14.

Gen AI served as the self-proclaimed “to start with” meeting focused to generative AI, which ingests extensive sums of human-created facts and, from that, learns how to mimic human creation. It could be the initially of numerous to come. 

Roughly 1,200 persons gathered at Pier 27 for Gen AI, which Jasper, a startup that has lifted more than $140 million, hosted. It brought jointly top providers in the market, which include the startups Anthropic and Stability AI.

The meeting comes at an intriguing moment for generative AI. This earlier November, OpenAI unveiled ChatGPT, the chatbot that captured the internet’s creativeness with its capacity to answer to just about any query using full paragraphs nearly indistinguishable from a thing a human would publish. Though the buzz around generative AI is reminiscent of the crypto and World wide web3 buzz

Read More

InnoCare Releases 2021 Annual Results and Business Highlights

BEIJING, March 22, 2022 /PRNewswire/ — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of 31 December 2021.

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “We are delighted to announce 2021 results on the occasion of our 2nd anniversary of listing on Hong Kong Stock Exchange. We have witnessed an unusual year 2021, in which we overcame tremendous difficulties and challenges and achieved many significant milestones. We have achieved satisfactory results in the first year of commercialization. The inclusion of orelabrutinib in the National Reimbursement Drug List (NRDL) at the end of 2021 will help access to more patients. We have made major breakthroughs in internationalization by reaching license-out and license-in collaboration with Biogen and Incyte respectively. We have deepened our efforts in innovation and accelerated the progress of our global multicenter clinical trials so as to further advance our drug candidate to benefit more patients…”

Financial Highlights

  • The revenue increased sharply from 1.4 million for the year ended 31 December 2020 to 1.043 billion for the year ended 31 December 2021, due to sales of orelabrutinib and upfront payment from Biogen.

  • The research and development expenses increased from 402.8 million for the year ended 31 December 2020 to 721.6 million for the year ended 31 December 2021, primarily due to the upfront payment of tafasitamab license-in, etc.

  • The cash and cash equivalent increased from 3.9696 billion by the end of 2020 to 6.5505 billion by the end of 2021.

  • The loss for the reporting period decreased from 391.9 million for the year ended 31 December 2020 to 66.7 million for the year ended 31 December 2021, mainly due to the increase of revenue, etc.

(Note: Currency: RMB)


Read More